Nurix therapeutics reports first quarter fiscal 2024 financial results and provides a corporate update

Extended the strategic collaboration with gilead sciences extended the strategic collaboration with sanofi to develop novel orally available targeted protein degrader of stat6 presented new case studies on nx-5948 demonstrating clinical responses in patients with cns lymphoma and cll with cns involvement announced that it is part of a team of experts selected as awardees in this year's cancer grand challenges san francisco, april 10, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended february 29, 2024, and provided a corporate update. “nurix had a strong start to 2024 with the recent announcements of the extensions of our collaborations with both gilead and sanofi further validating the power of our platform and the expansion of our work in inflammatory diseases with sanofi, including the stat6 program, one of the most exciting targets in inflammation,” said arthur t.
NRIX Ratings Summary
NRIX Quant Ranking